Hikma Pharmaceuticals (OTCMKTS:HKMPF) Hits New 12-Month High – Should You Buy?

Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $28.14 and last traded at $28.14, with a volume of 100 shares trading hands. The stock had previously closed at $26.64.

Analysts Set New Price Targets

Separately, Royal Bank of Canada raised shares of Hikma Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Tuesday, December 10th.

Hikma Pharmaceuticals Trading Up 5.6 %

The company has a quick ratio of 0.98, a current ratio of 1.66 and a debt-to-equity ratio of 0.46. The stock has a 50 day moving average price of $24.94 and a 200-day moving average price of $24.98.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.